Peter Dolan

Mr. Dolan is Chairman of the Board of Trustees of Tufts University. He was elected Chair in 2013, having served on the Tufts Board since 2001. He is Chairman of the Board of the Partnership for A Healthier America and has served on that Board since 2010. He is also currently on the Board of Amplitude Health Care (healthcare SPAC). Previously, from 1988-2006, Mr. Dolan was at Bristol-Myers Squibb, eventually serving as Chairman and CEO, and as CEO. He joined Bristol-Myers Squibb from General Foods. After more than a decade leading the BMS Consumer Products, Nutritionals, and Medical Device businesses, he was named CEO in 2001 at age 45. As CEO, he led the acquisition of DuPont Pharmaceuticals, which brought Eliquis to the company, and by 2019, Eliquis was the second largest drug in global industry annual prescription drug revenue. In 2001, the successful investment in Imclone’s Erbitux successfully bolstered Bristol-Myers Squibb’s oncology business until the introductions of blockbusters Sprycel and Yervoy. Ushering the company into biologics, in 2004 Mr. Dolan licensed the immuno-oncology compound that became Yervoy, named the Biotech Discovery of the Decade in 2016 for extending survival in some of the hardest to treat forms of cancer. In 2006, he strengthened the company’s commitment to biologics with the largest capital investment in the company’s history to build the first Bristol-Myers Squibb biologics manufacturing facility.

Post Bristol-Myers Squibb, he has served as Chairman and CEO of GeminX, a venture capital backed startup oncology company that was successfully sold to Cephalon Pharmaceuticals for $225 million.

Throughout his career, Mr. Dolan has served on the boards of multiple for-profits and not-for-profits, including the American Express Company, ChildObesity180 (as Chairman) and the Tuck School Board of Overseers. Mr. Dolan graduated magna cum laude from Tufts University in 1978 with a Bachelor of Arts degree. He then earned an MBA from the Tuck School of Business at Dartmouth College in 1980.

Dr. Nitin Nohria, PhD

Distinguished Service University Professor, Harvard University. Former Dean of Harvard Business School.

Nitin Nohria served as the tenth dean of Harvard Business School for a decade from 2010-2020. He previously served as co-chair of the Leadership Initiative, Senior Associate Dean of Faculty Development, and Head of the Organizational Behavior unit.

As Dean, he identified five priorities for Harvard Business School:  innovation in the School's educational programs; intellectual ambition to advance ideas with impact in practice; internationalization to expand global engagement; inclusion to enable every member of the community to do their best work in support of the School's mission; and integration within HBS and across Harvard University to fully leverage its collective strengths.  Examples of activities successfully implemented in support of these priorities include:

• Field Immersion Experiences for Leadership Development (FIELD), that provides students with intensive, immersive, opportunities to develop the knowing, doing, and being of leadership.

• The U.S. Competitiveness Project, a multi-faculty research-led effort to understand and improve the ability of firms operating in the U.S. to compete successfully in the global economy.

• The launch of the Harvard Innovation Labs, to foster entrepreneurial activities and deepen interactions among Harvard students, faculty, and members of the Greater Boston community.

Harvard Business School Online, the School's digital platform that brings the dynamism of the HBS classroom to online learning.

Professor Nohria's intellectual interests center on leadership (especially the role of the CEO), corporate and digital transformation, management of multinational corporations, and sustainable economic and human performance.  He is co-author or co-editor of 16 books and over 100 journal articles, book chapters, cases, working papers, and notes.  His HBR article on “How CEOs Manage Time,” was the winner of the McKinsey prize and his book Differentiated Network: Organizing Multinational Corporations for Value Creation, the winner of the Terry prize by the Academy of Management.  He has also written for the Wall Street Journal, The Atlantic, Washington Post, Financial Times, and Boston Globe.

He sits on the board of directors of Bridgespan and on the board of trustees of Massachusetts General Hospital.  In addition, he serves as a senior advisor to BDT Capital Partners, Piramal Enterprises, and Tata Sons (where he served on the board of directors for 6 years).  He is also on the advisory board of Akshaya Patra and ShopX, and is a strategic advisor to Focusing Capital on the Long Term Global (FCLTGlobal).

Prior to joining the Harvard Business School faculty in July 1988, Dean Nohria received his Ph.D. in Management from the Sloan School of Management, Massachusetts Institute of Technology, and a B. Tech. in Chemical Engineering from the Indian Institute of Technology, Bombay (which honored him as a Distinguished Alumnus in 2007).  He was a visiting faculty member at the London Business School in 1996.

John Ripple

John Ripple is the founder of Ripple Biotech, LLC, which advises biopharmaceutical companies on strategy, business development, and capital fundraising activities. He previously served as CEO of five venture-backed biotech companies, including Exonics Therapeutics (acquired by Vertex), Virdante Pharmaceuticals (acquired by Momenta), and Syntonix Pharmaceuticals (acquired by Biogen).

John has also held positions in business development, medical device marketing, and management consulting, and as entrepreneur in residence. He started his career as an aerospace engineer at NASA. He currently serves as a member on the Board of Overseers at the Marine Biological Laboratory (Woods Hole, MA), and on the Board of Directors and as Treasurer of the Children’s Melanoma Prevention Foundation.

John received a BS in Mechanical Engineering from Bucknell University, and an MBA from Harvard Business School.

Murali Doraiswamy, MD

Murali Doraiswamy is a Professor of Psychiatry and Medicine at Duke University School of Medicine and a member of the Duke Institute for Brain Sciences.  He is also a Senior Fellow at the Duke Center for the Study of Aging and an Affiliate Faculty at the Duke Center for Precision Medicine and Applied Genomics as well as the Duke Microbiome Center.  He directs a clinical trials unit that has been involved in the development of many diagnostics and therapeutics in wide use today.

 

Professor Doraiswamy has been an advisor to leading government agencies, businesses and advocacy groups including the NIH, FDA, and WHO as well as numerous life science companies. He has served as the chair of the World Economic Forum's Global Agenda Council on Brain Research and has lectured at leading global forums to advance the forefront of aging and neuroscience research.

 

Moreover, as an investigator on numerous landmark trials and co-author on more than 400 publications, he has received several awards in recognition of his scientific work.  Additionally, he is a leading advocate for increasing funding for brain and behavioral research.  He is the co-author of a popular book The Alzheimer’s Action Plan.     

Dr. Li Tso, MD

Dr. Tso is a clinician, internal medicine, and co-medical director for Bulfinch Medical Group (BMG) at Massachusetts General Hospital. BMG is a large primary care practice at MGH with over 80 employees and nearly 20,000 patients. Over thirty plus years, Dr. Tso is estimated to have had over 100,000 patient encounters. His particular clinical interests include hypertension, preventive cardiology, sports medicine, and prevention of chronic medical conditions.

 

He is also currently an Assistant Professor of Medicine at Harvard Medical School.  Since 2011, he continues to serve as the team physician and internist for the New England Patriots football team.  He graduated magna cum laude from Harvard University with a degree in Chemistry and received his M.D. from SUNY at Stony Brook. He completed his internship, residency in internal medicine, and fellowship in nephrology at the Massachusetts General Hospital.       

Advisors
 
Peter Dolan
Dr. Nitin Nohria, PhD

Distinguished Service University Professor, Harvard University. Former Dean of Harvard Business School.

Dr. Nohria served as the tenth dean of Harvard Business School for a decade from 2010-2020. He previously served as co-chair of the Leadership Initiative, Senior Associate Dean of Faculty Development, and Head of the Organizational Behavior unit.

As Dean, he identified five priorities for Harvard Business School:  innovation in the School's educational programs; intellectual ambition to advance ideas with impact in practice; internationalization to expand global engagement; inclusion to enable every member of the community to do their best work in support of the School's mission; and integration within HBS and across Harvard University to fully leverage its collective strengths.  Examples of activities successfully implemented in support of these priorities include:

• Field Immersion Experiences for Leadership Development (FIELD), that provides students with intensive, immersive, opportunities to develop the knowing, doing, and being of leadership.

• The U.S. Competitiveness Project, a multi-faculty research-led effort to understand and improve the ability of firms operating in the U.S. to compete successfully in the global economy.

• The launch of the Harvard Innovation Labs, to foster entrepreneurial activities and deepen interactions among Harvard students, faculty, and members of the Greater Boston community.

Harvard Business School Online, the School's digital platform that brings the dynamism of the HBS classroom to online learning.

Professor Nohria's intellectual interests center on leadership (especially the role of the CEO), corporate and digital transformation, management of multinational corporations, and sustainable economic and human performance.  He is co-author or co-editor of 16 books and over 100 journal articles, book chapters, cases, working papers, and notes.  His HBR article on “How CEOs Manage Time,” was the winner of the McKinsey prize and his book Differentiated Network: Organizing Multinational Corporations for Value Creation, the winner of the Terry prize by the Academy of Management.  He has also written for the Wall Street Journal, The Atlantic, Washington Post, Financial Times, and Boston Globe.

Dr. Nohria sits on the board of directors of Bridgespan and on the board of trustees of Massachusetts General Hospital.  In addition, he serves as a senior advisor to BDT Capital Partners, Piramal Enterprises, and Tata Sons (where he served on the board of directors for 6 years).  He is also on the advisory board of Akshaya Patra and ShopX, and is a strategic advisor to Focusing Capital on the Long Term Global (FCLTGlobal).

Prior to joining the Harvard Business School faculty in July 1988, Dean Nohria received his Ph.D. in Management from the Sloan School of Management, Massachusetts Institute of Technology, and a B. Tech. in Chemical Engineering from the Indian Institute of Technology, Bombay (which honored him as a Distinguished Alumnus in 2007).  He was a visiting faculty member at the London Business School in 1996.

John Ripple

Mr. Ripple is the founder of Ripple Biotech, LLC, which advises biopharmaceutical companies on strategy, business development, and capital fundraising activities. He previously served as CEO of five venture-backed biotech companies, including Exonics Therapeutics (acquired by Vertex), Virdante Pharmaceuticals (acquired by Momenta), and Syntonix Pharmaceuticals (acquired by Biogen).

John has also held positions in business development, medical device marketing, and management consulting, and as entrepreneur in residence. He started his career as an aerospace engineer at NASA. He currently serves as a member on the Board of Overseers at the Marine Biological Laboratory (Woods Hole, MA), and on the Board of Directors and as Treasurer of the Children’s Melanoma Prevention Foundation.

John received a BS in Mechanical Engineering from Bucknell University, and an MBA from Harvard Business School.

Dr. Murali Doraiswamy, MD

Dr. Doraiswamy is a Professor of Psychiatry and Medicine at Duke University School of Medicine and a member of the Duke Institute for Brain Sciences.  He is also a Senior Fellow at the Duke Center for the Study of Aging and an Affiliate Faculty at the Duke Center for Precision Medicine and Applied Genomics as well as the Duke Microbiome Center.  He directs a clinical trials unit that has been involved in the development of many diagnostics and therapeutics in wide use today.

 

Professor Doraiswamy has been an advisor to leading government agencies, businesses and advocacy groups including the NIH, FDA, and WHO as well as numerous life science companies. He has served as the chair of the World Economic Forum's Global Agenda Council on Brain Research and has lectured at leading global forums to advance the forefront of aging and neuroscience research.

 

Moreover, as an investigator on numerous landmark trials and co-author on more than 400 publications, he has received several awards in recognition of his scientific work.  Additionally, he is a leading advocate for increasing funding for brain and behavioral research.  He is the co-author of a popular book The Alzheimer’s Action Plan.     

Dr. Li Tso, MD

Dr. Tso is a clinician, internal medicine, and co-medical director for Bulfinch Medical Group (BMG) at Massachusetts General Hospital. BMG is a large primary care practice at MGH with over 80 employees and nearly 20,000 patients. Over thirty plus years, Dr. Tso is estimated to have had over 100,000 patient encounters. His particular clinical interests include hypertension, preventive cardiology, sports medicine, and prevention of chronic medical conditions.

 

He is also currently an Assistant Professor of Medicine at Harvard Medical School.  Since 2011, he continues to serve as the team physician and internist for the New England Patriots football team.  He graduated magna cum laude from Harvard University with a degree in Chemistry and received his M.D. from SUNY at Stony Brook. He completed his internship, residency in internal medicine, and fellowship in nephrology at the Massachusetts General Hospital.       

Dr. Todd Herrington, MD, PhD

Dr. Herrington is an Assistant Professor of Neurology at Harvard Medical School and the director of the Deep Brain Stimulation (DBS) program at Massachusetts General Hospital. His research is focused on understanding the impact of DBS on motor and non-motor symptoms of Parkinson’s disease with the goal of developing new approaches to neuromodulation.

 

In addition, he has helped advance novel approaches for Parkinson's treatment including the development of autologously derived dopaminergic cell therapy.  Dr. Herrington has been a principal investigator on both investigator-initiated and industry-sponsored clinical trials in Parkinson’s disease, and has received research support from the National Institutes of Health, American Academy of Neurology and the Bachmann Strauss Dystonia and Parkinson’s Foundation. He received his MD and PhD degrees from Harvard Medical School and completed his training in Neurology at Massachusetts General and Brigham and Women’s Hospitals.      

Dr. Ganesh Kaundinya, PhD

Dr. Kaundinya is an entrepreneur and seasoned executive with track record of creating impact in the biotech and healthcare sector.  Dr. Kaundinya founded Momenta Pharmaceuticals based on technology he invented at MIT (Momenta Pharmaceuticals was acquired by Johnson and Johnson for US $6.5Billion in August 2020).  As the Founder, CSO and COO, Dr. Kaundinya built the company from a nascent technology concept to a multi-billion dollar, publicly traded enterprise with 3 FDA-approved commercial products and a deep pipeline of products in development.  The portfolio includes novel biological products (mAbs and fusion protein) in auto-immune diseases, rare orphan diseases, opthamology, oncology, multiple sclerosis, and thrombosis.  As the Chief Operations Officer, he was responsible for all aspects of operations including research, pre-clinical and clinical development, manufacturing, regulatory affairs, commercial, program & alliance management.  He led a group of over 250 people and managed an annual budget of ~200M$.  Dr. Kaundinya was a member of the Joint Steering Committees for the major collaborations with Novartis, Baxter/Baxalta/Shire, CSL Behring, Mylan, GSK and Wuxi.  He worked closely with C-level executives from these companies in shaping the strategy and managing the execution of the collaborations.  As the Chief scientific Officer, he was also responsible for advancing the science, product development and strategy as well as in-licensing assets.

 

Presently, Dr. Kaundinya is mentoring, and on the board of multiple early-stage companies, working with investors and management teams to translate scientific innovations, develop corporate strategy and raise capital.  His portfolio of companies span varied technologies including: AI applications in healthcare, gene editing for rare orphan diseases, microbiome for neurological diseases, electromagnetic devices for brain therapy and BCI, and recombinant food technology as alternatives to animal products.  He is also involved in development of a therapeutic for Covid-19 that is based on targeting spike protein (with Momenta Pharmaceuticals) and is a strategic advisor for Biological E Ltd, an international vaccine company. 

Previously, Dr. Kaundinya was research faculty member at the Harvard-MIT Division of Health Sciences and Technology and later at the MIT Division of Bioengineering.  Dr. Kaundinya was the Director of Bioinformatics at MIT for a multi-center project on evaluating roles of complex polysaccharides in biology.  Dr. Kaundinya has authored more than 120 scientific publications and over 70 patents and patent applications.  Dr. Kaundinya earned both his M.S. and Ph.D. in Chemical Engineering from Massachusetts Institute of Technology. 

Mr. Dolan is Chairman of the Board of Trustees of Tufts University. He was elected Chair in 2013, having served on the Tufts Board since 2001. He is Chairman of the Board of the Partnership for A Healthier America and has served on that Board since 2010. He is also currently on the Board of Amplitude Health Care (healthcare SPAC). Previously, from 1988-2006, Mr. Dolan was at Bristol-Myers Squibb, eventually serving as Chairman and CEO, and as CEO. He joined Bristol-Myers Squibb from General Foods. After more than a decade leading the BMS Consumer Products, Nutritionals, and Medical Device businesses, he was named CEO in 2001 at age 45. As CEO, he led the acquisition of DuPont Pharmaceuticals, which brought Eliquis to the company, and by 2019, Eliquis was the second largest drug in global industry annual prescription drug revenue. In 2001, the successful investment in Imclone’s Erbitux successfully bolstered Bristol-Myers Squibb’s oncology business until the introductions of blockbusters Sprycel and Yervoy. Ushering the company into biologics, in 2004 Mr. Dolan licensed the immuno-oncology compound that became Yervoy, named the Biotech Discovery of the Decade in 2016 for extending survival in some of the hardest to treat forms of cancer. In 2006, he strengthened the company’s commitment to biologics with the largest capital investment in the company’s history to build the first Bristol-Myers Squibb biologics manufacturing facility.

Post Bristol-Myers Squibb, he has served as Chairman and CEO of GeminX, a venture capital backed startup oncology company that was successfully sold to Cephalon Pharmaceuticals for $225 million.

Throughout his career, Mr. Dolan has served on the boards of multiple for-profits and not-for-profits, including the American Express Company, ChildObesity180 (as Chairman) and the Tuck School Board of Overseers. Mr. Dolan graduated magna cum laude from Tufts University in 1978 with a Bachelor of Arts degree. He then earned an MBA from the Tuck School of Business at Dartmouth College in 1980.